Steatotic Liver Disease: What You Need to Know, Part 1. Steatotic Liver Disease at the Crossroads—Bridging Alcohol-Associated Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Era of Multimorbidity

Nov 08 2025
Convention Center: Ballroom A, Level 3
8:00 AM - 9:30 AM

World Class Speakers

Veeral Ajmera, MD
Presenter

Veeral Ajmera, MD

University of California, San Diego
Miriam B. Vos, MD, MSPH, FAASLD
Presenter

Miriam B. Vos, MD, MSPH, FAASLD

Emory University, Children's Healthcare of Atlanta
Brian P Lee, MD
Presenter

Brian P Lee, MD

Keck School of Medicine
Gerald Scott Winder, MD MSc FACLP
Presenter

Gerald Scott Winder, MD MSc FACLP

Henry Ford Health
Elizabeth Lee, MN, NP, CGN(C)
Moderator

Elizabeth Lee, MN, NP, CGN(C)

Toronto General Hospital

Description

Speakers delve into the intersections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on how multimorbidity—such as obesity, diabetes, and cardiovascular disease—complicates diagnosis, management, and prognosis. Experts discuss the shared and unique pathophysiological mechanisms, the role of genetic and behavioral risk factors, and the importance of a multidisciplinary approach to patient care.

Journey Maps

Presentations

8:00 AM - 8:15 AM
Nov 08 2025
Washington, D.C.

Genetic Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease, MetALD, and Alcohol-Associated Liver Disease: Should It Be Incorporated Into Clinical Practice?

Veeral Ajmera, MD, Presenter
ALD
MASLD
8:15 AM - 8:30 AM
Nov 08 2025
Washington, D.C.

Pediatric Steatotic Liver Disease: What's New and Where Should We Go Next?

Miriam B. Vos, MD, MSPH, FAASLD, Presenter
ALD
MASLD
8:30 AM - 8:45 AM
Nov 08 2025
Washington, D.C.

Screening and Risk Stratification in MetALD: How to Account for Multiple Contributors of Disease?

Brian P Lee, MD, Presenter
ALD
MASLD
8:45 AM - 9:00 AM
Nov 08 2025
Washington, D.C.

Steatotic Liver Disease: Role of Behavioral Health in Managing Weight and Alcohol Use

Gerald Scott Winder, MD MSc FACLP, Presenter
ALD
MASLD
9:00 AM - 9:15 AM
Nov 08 2025
Washington, D.C.

Natural History and Disease Progression of MetALD

Juan Pablo Arab, MD, FRCPC, Presenter
ALD
MASLD
9:15 AM - 9:30 AM
Nov 08 2025
Washington, D.C.

Q&A Session

Elizabeth Lee, MN, NP, CGN(C), Moderator
ALD
MASLD

Objectives

  • Explain the connections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), including their overlapping risk factors and pathways.
  • Review the role of multimorbidity in shaping disease outcomes in steatotic liver diseases.
  • Discuss strategies for integrating ALD and MASLD management into clinical practice.
Chair

Mazen Noureddin, MD, MHSc

Houston Methodist Hospital
Chair

Juan Pablo Arab, MD, FRCPC

Virginia Commonwealth University